In my March 9, 2023 post, I disclosed a new position in BlackRock, Inc. (BLK) in a 'Core' account in the FFJ Portfolio with the purchase of 60 shares @ ~$664. I subsequently acquired: 40 shares on April 26 @ ~$656; and 30 shares @ ~$635 on May 9 (refer to my May 12 post) [...]
In my October 5 guest post at Dividend Power, I present my thoughts on why you should consider Intercontinental Exchange (ICE) as a potential investment given its record of consistent growth and value creation. Some investors make investment decisions based solely on share price behaviour. Share price behaviour, however, does not necessarily always reflect a [...]
Some investors who acquired Nike (NKE) shares in 2021 when they were overvalued, wouldn't consider buying shares now that they are undervalued. Other investors who fixate on stock charts will look at NKE's mid-September 2019 share price and the current share price (~$90 as I compose this post) only to find they are fairly similar [...]
I last reviewed Paychex (PAYX) in this June 30 post at which time I determined shares were attractively valued. This was encouraging considering that for the past several months I struggled to identify fairly or attractively valued high-quality companies. Fortunately, the valuation pendulum has swung significantly of late thus presenting investors with a larger pool [...]
I last reviewed Copart (CPRT) in this September 10, 2022 post at which time I disclosed the purchase of an additional 100 shares in the FFJ Portfolio. Following that purchase, my total CPRT exposure consisted of 450 shares. On November 4, 2022, CPRT initiated a 2-for-1 stock split thereby doubling my holdings to 900; the [...]
In my September 14 guest post at Dividend Power, I discuss how Nasdaq (NDAQ) is transforming future capital markets. I first reviewed NDAQ in this October 21, 2021 post at which time I decided not to initiate a position. On June 12, 2023, however, NDAQ announced that it entered into a definitive agreement to acquire [...]
In my August 16 Agilent Technologies (A) post, I disclosed the following purchases: 100 shares @ ~$115.96/share on June 9; the forward adjusted diluted PE level was ~20.6. 100 shares @ ~$118.48/share on July 6; the forward adjusted diluted PE level was ~21.1. With the recent weakness in A's share price, I deem A's valuation [...]
In my July 29 post, I reviewed RTX Corporation (RTX) following the release of Q2 and YTD2023 results. In releasing Q2 results, RTX informed the investment community that its Pratt & Whitney (P&W) operating segment identified microscopic contaminants in a metal used in part of the Geared Turbofan (GTF) engines that power Airbus' popular A320neo [...]
I last reviewed Thermo Fisher Scientific (TMO) in this August 2 post at which time Q2 and YTD2023 results had recently been released; I concluded shares were overvalued at ~$544. Following that post: TMO completed the CorEvitas acquisition I touched upon in my previous post. Novo Nordisk hired TMO to help fill the injection pens [...]
In my August 26 Rollins (ROL) post, I reference the company's $1.5B shelf registration. One of the purposes of this shelf registration was to provide the company with liquidity to help the Rollins family divest a portion of their holdings. I concluded that post by stating 'Although ROL shares are not inexpensive, I intend to [...]